CytoDyn Submits Phase IIb Protocol for PRO 140 Clinical Trial to FDA

Published: Oct 31, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (“CytoDyn”) (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn’s leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.

Help employers find you! Check out all the jobs and post your resume.

Back to news